【摘要】 <正> 1966年Djerassi首先应用大剂量氨甲喋呤治疗抗药性白血病,至今已较广泛用于急性白血病、非何杰金淋巴瘤、骨肉瘤和其它实体瘤的治疗。最近报道最大剂量已达30g/m~2以上。本文报道采用大剂量氨甲喋呤合并甲酰四氢叶酸钙(以下简称HDMTX-CF)治疗11例晚期抗药性恶性肿瘤,其中6例进行了MTX血药浓度的监测。更多还原

【Abstract】 We studied the use of High-Dose Methotrexate(0. 5-6. 0g) with citrovorum factor(RDMTX-CF) in 11 patients with advanced refractory malignant lymphoma andother solid tumors and determined the plasma concentration of MTX at 0,24, 48 and72h after its administration in six patients. Our preliminary results suggest thatHDMTX-CF may be useful as salvage therapy in patients with resistant-conventionalchemotherapy malignant lymphoma. and breast carcinoma and also as postoperativeadjuvant chemotherapy in cases with osteogenic sarcoma. The data further confirm thatthe lethal toxicity of RDMTX-CF is mainly related to the clearance of MTX from body.更多还原